MARKET

SYN

SYN

SYNTHETIC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.3700
-0.0065
-1.73%
After Hours: 0.3710 +0.001 +0.27% 17:38 12/04 EST
OPEN
0.3600
PREV CLOSE
0.3765
HIGH
0.3794
LOW
0.3600
VOLUME
248.24K
TURNOVER
--
52 WEEK HIGH
0.7500
52 WEEK LOW
0.2522
MARKET CAP
7.40M
P/E (TTM)
-0.5237
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American
, /PRNewswire/ --  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that on , the NYSE American LLC ("NYSE American"), the Company's current listing exchange, notified the Company that it had been granted an extension until to regain compliance with certain continued listing standards as set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.  
PR Newswire - PRF · 11/24 12:00
Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that on November 23, 2020, the NYSE American LLC ("NYSE American"), the Company's current listing exchange, notified the Company that it had been granted an extension until May 25, 2021 to regain compliance with certain continued listing standards as set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.
PR Newswire · 11/24 12:00
Synthetic Biologics Engages A.G.P./Alliance Global Partners aA Advisor To Assist In Evaluating Strategic Options Including Potentially In-Licensing Or Acquiring Assets
ROCKVILLE, Md., Nov. 16, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and
Benzinga · 11/16 12:06
Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options
, /PRNewswire/ --  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has engaged A.G.P./Alliance Global Partners to assist the Company in exploring and evaluating a range of strategic options. The engagement, which was approved by the Company's Board of Directors, is intended to optimize the Company's ability to maximize growth while increasing value for its shareholders.  
PR Newswire - PRF · 11/16 12:00
Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has engaged A.G.P./Alliance Global Partners to assist the Company in exploring and evaluating a range of strategic options. The engagement, which was approved by the Company's Board of Directors, is intended to optimize the Company's ability to maximize growth while increasing value for its shareholders.
PR Newswire · 11/16 12:00
Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
, /PRNewswire/ --  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced the appointment of senior biotech executive , PhD, to the Company's Board of Directors, effective immediately. Dr. Monahan replaces who has stepped down after serving on the board since 2012.     
PR Newswire - PRF · 11/12 12:00
Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
PR Newswire · 11/12 12:00
Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results
, /PRNewswire/ --  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended .
PR Newswire - PRF · 11/10 21:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYN. Analyze the recent business situations of SYNTHETIC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYN stock price target is 1.250 with a high estimate of 1.250 and a low estimate of 1.250.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 1.75M
% Owned: 8.74%
Shares Outstanding: 19.99M
TypeInstitutionsShares
Increased
3
253.42K
New
2
98.10K
Decreased
6
47.38K
Sold Out
5
523.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Kraws
Chief Executive Officer/Chief Financial Officer/Director
Steven Shallcross
Director
John Monahan
Independent Director
Jeffrey Wolf
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SYN
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Synthetic Biologics Inc stock information, including AMEX:SYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYN stock methods without spending real money on the virtual paper trading platform.